ArticleScientific reports2025
Exploration of 1-(2,4-difluorophenyl)-5-oxopyrrolidine-3-carboxylic acid derivatives effect on triple-negative breast, prostate cancer and melanoma cell 2D and 3D cultures.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cell Line-Dependent Effects of Spheroid Formation Method on Drug Response in Melanoma Models.Cells · 2026Article
- Synthesis and Development of 3-((2,4-Difluorophenyl)Amino)Propanoic Acid Derivatives as an Antiproliferative Medicinal Chemistry Scaffold Targeting Growth Factor Receptors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Synthesis and anticancer evaluation of novel thioimidazole derivatives bearing a trimethoxyphenyl moiety.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1-Substituted 5-oxopyrrolidine-3-carboxylic acid and its derivatives play an important role as components of many biologically active molecules. This study describes the synthesis of 1-(2,4-difluorophenyl)-5-oxopyrrolidine-3-carboxylic acid derivatives and their anticancer properties. The target compounds were prepared using 2,4-difluoroniline as a starting material; in this way, derivatives of benzimidazoles, hydrazones and azoles were formed. Investigation of the anticancer activity of all synthesized compounds showed that the hydrazones had the strongest effect on cancer cell lines. Compounds were tested for their cytotoxic effect by the MTT assay in human triple-negative breast cancer MDA-MB-231, prostate adenocarcinoma PPC1, melanoma A375 and human foreskin fibroblasts CRL-4001 after 72 hours of incubation. The impact of the compounds on cancer cell migration was assessed using a 'wound healing assay'. Activity in 3D cultures was determined by evaluating changes in spheroid size and assessing cell viability. Overall, the selected compounds 7b, 9c, 9e, 9f and 10 exhibited greater activity in the A375 cell line and were less active against the MDA-MB-231 cell line. Compounds 9c, 9e and 10 showed relatively higher selectivity for cancer cells over fibroblasts. Hydrazone 9f, bearing N'-(4-methylbenzylidene) moiety, was identifiedasthe most cytotoxic compound in both prostate adenocarcinoma PPC-1 and melanoma A375 cells in monolayer and 3D culture models. Compound 9e, with N'-(4-bromobenzylidene) moiety, exhibited the most pronounced inhibitory effect on cell migration as determined by the 'wound healing' assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.